CY1113845T1 - Παραγωγο διβενζοθειαζεπινης και χρηση αυτου - Google Patents

Παραγωγο διβενζοθειαζεπινης και χρηση αυτου

Info

Publication number
CY1113845T1
CY1113845T1 CY20131100246T CY131100246T CY1113845T1 CY 1113845 T1 CY1113845 T1 CY 1113845T1 CY 20131100246 T CY20131100246 T CY 20131100246T CY 131100246 T CY131100246 T CY 131100246T CY 1113845 T1 CY1113845 T1 CY 1113845T1
Authority
CY
Cyprus
Prior art keywords
disorder
divenzotheiazepin
production
compounds
schizophrenia
Prior art date
Application number
CY20131100246T
Other languages
Greek (el)
English (en)
Inventor
Dean Brown
James R Damewood
Phil Edwards
James Hulsizer
James Campbell Muir
Jr M Edward Pierson
Ashokkumar Bhikkappa Shenvi
Steven Wesolowski
Dan Widzowski
Michael Wood
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41431860&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1113845(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CY1113845T1 publication Critical patent/CY1113845T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
CY20131100246T 2008-06-20 2013-03-22 Παραγωγο διβενζοθειαζεπινης και χρηση αυτου CY1113845T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7441708P 2008-06-20 2008-06-20
EP09766953A EP2307389B1 (en) 2008-06-20 2009-06-18 Dibenzothiazepine derivative and use thereof

Publications (1)

Publication Number Publication Date
CY1113845T1 true CY1113845T1 (el) 2016-07-27

Family

ID=41431860

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20131100246T CY1113845T1 (el) 2008-06-20 2013-03-22 Παραγωγο διβενζοθειαζεπινης και χρηση αυτου

Country Status (37)

Country Link
US (3) US20110160184A1 (enExample)
EP (1) EP2307389B1 (enExample)
JP (2) JP5468068B2 (enExample)
KR (1) KR20110019781A (enExample)
CN (1) CN102131791B (enExample)
AR (1) AR072200A1 (enExample)
AU (1) AU2009260905B2 (enExample)
BR (1) BRPI0914231A2 (enExample)
CA (1) CA2728675A1 (enExample)
CL (1) CL2010001471A1 (enExample)
CR (1) CR11860A (enExample)
CU (1) CU23884B1 (enExample)
CY (1) CY1113845T1 (enExample)
DK (1) DK2307389T3 (enExample)
DO (1) DOP2010000393A (enExample)
EA (1) EA201001889A1 (enExample)
EC (1) ECSP10010698A (enExample)
ES (1) ES2402084T3 (enExample)
HN (1) HN2010002683A (enExample)
HR (1) HRP20130234T1 (enExample)
IL (2) IL210081A (enExample)
ME (1) ME01516B (enExample)
MX (1) MX2010014203A (enExample)
MY (1) MY157518A (enExample)
NI (1) NI201000224A (enExample)
NZ (1) NZ590616A (enExample)
PE (1) PE20110029A1 (enExample)
PL (1) PL2307389T3 (enExample)
PT (1) PT2307389E (enExample)
RS (1) RS52703B (enExample)
SI (1) SI2307389T1 (enExample)
SV (1) SV2010003769A (enExample)
TW (1) TWI488854B (enExample)
UA (1) UA105903C2 (enExample)
UY (1) UY31919A (enExample)
WO (1) WO2009154563A1 (enExample)
ZA (1) ZA201100488B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2728675A1 (en) * 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
US20160205082A1 (en) * 2013-08-12 2016-07-14 Graphite Software Corporation Secure authentication and switching to encrypted domains
CN103524455A (zh) * 2013-10-30 2014-01-22 苏州敬业医药化工有限公司 一种制备2-氯-二苯并[b,f][1,4]硫氮杂卓-11-[10H]酮的方法
WO2015074150A1 (en) 2013-11-21 2015-05-28 Graphite Software Corporation Managed domains for remote content and configuration control on mobile information devices
CN104447615A (zh) * 2014-02-28 2015-03-25 广东东阳光药业有限公司 喹硫平中间体的制备方法
JP2026509430A (ja) * 2023-03-08 2026-03-19 ヨハン ヴォルフガング ゲーテ－ウニベルジテート フランクフルト アム マイン Ｓｌａｃｋ活性化化合物及びその医学的用途
EP4428132A1 (en) * 2023-03-08 2024-09-11 Johann-Wolfgang-Goethe-Universität Frankfurt am Main Slack-activating compounds and their medical use

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL293201A (enExample)
NL294355A (enExample)
DE1620703B2 (de) * 1960-08-16 1976-11-25 Ausscheidung aus: 12 80 879 Dr. A. Wander AG, Bern 11-basisch substituierte dibenzo eckige klammer auf b,f eckige klammer zu-eckige klammer auf 1,4 eckige klammer zu-thiazepine
CH422793A (de) * 1961-07-20 1966-10-31 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo(b,f) (1,4)thiazepine
CH476753A (de) 1962-06-08 1969-08-15 Wander Ag Dr A Verfahren zur Herstellung von 11-basisch substituierter Dibenzo(b,f)(1,4)thiazepine
DE1620712A1 (de) * 1962-05-25 1970-06-04 Wander Ag Dr A Verfahren zur Herstellung 11-basisch substituierter Dibenzo-[b,f][1,4]-thiazepine
NL140242B (nl) 1963-03-01 1973-11-15 Wander Ag Dr A Werkwijze voor het bereiden van op de 11-plaats door een basische groep gesubstitueerde dibenz (b.f.)(1.4) oxazepinen.
NL293210A (enExample) 1963-05-09
US3908010A (en) 1967-03-22 1975-09-23 Wander Ag Dr A Basically substituted heterocycles as anti-emetics
US3884920A (en) 1967-07-14 1975-05-20 Sandoz Ag 11-Basically substituted dibenz {8 b,f{9 {0 {8 1,4{9 {0 oxazepines
US3683034A (en) 1963-09-27 1972-08-08 Upjohn Co Process for the preparation of substituted hydroquinones
US3412193A (en) 1965-12-13 1968-11-19 American Cyanamid Co 11-(4-methyl-1-piperazinyl)dibenz[b, f][1, 4]oxazepines or thiazepines for controlling fertility
US3444169A (en) 1966-01-17 1969-05-13 American Cyanamid Co Process for 11 - aminodibenz(b,f)(1,4)oxazepines and analogous thiazepines
NL6715650A (enExample) 1966-12-16 1968-06-17
US3852446A (en) 1967-03-13 1974-12-03 Sandoz Ag Organic compounds in treatment of psychotic disturbances
US3758479A (en) 1967-03-22 1973-09-11 Sandoz Ag Nitro and sulphamoyl substituted dibenzodiazepines
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US3962248A (en) * 1972-04-04 1976-06-08 Sandoz, Inc. Process for making 11-piperazino-diazepines, oxazepines, thiazepines and azepines
CH569730A5 (enExample) * 1972-04-04 1975-11-28 Wander Ag Dr A
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
GB8705574D0 (en) 1987-03-10 1987-04-15 Ici Plc Preparation of thiazepine compound
JPH04211071A (ja) * 1990-03-05 1992-08-03 Hokuriku Seiyaku Co Ltd 多環式化合物
JPH0565257A (ja) 1991-07-05 1993-03-19 Hokuriku Seiyaku Co Ltd 多環式化合物及びその用途
US5750566A (en) 1994-08-12 1998-05-12 Eli Lilly And Company Synthetic excitatory amino acids
JP3708962B2 (ja) 1994-08-24 2005-10-19 アストラゼネカ・アクチエボラーグ 治療に有用なスピロ−アザ二環式化合物
US5602121A (en) * 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. Alkyl-substituted compounds having dopamine receptor affinity
SE9504661D0 (sv) 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9600683D0 (sv) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis
SE9702799D0 (sv) 1997-07-25 1997-07-25 Astra Ab New compounds
US6342488B1 (en) 1998-08-18 2002-01-29 Sepracor, Inc. Phosphonorisperidone and sulforisperidone compositions and methods
SE9900100D0 (sv) 1999-01-15 1999-01-15 Astra Ab New compounds
JP2003505505A (ja) 1999-07-28 2003-02-12 オスヴァルト・ヴィス 運動時の酸素消費を低下するための製剤
SE9903760D0 (sv) 1999-10-18 1999-10-18 Astra Ab New compounds
SE0002729D0 (sv) 2000-07-20 2000-07-20 Astrazeneca Ab Novel compound form
US6630462B2 (en) 2000-11-17 2003-10-07 Adolor Corporation Delta agonist analgesics
IL139975A0 (en) 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs
NZ539828A (en) 2001-05-18 2007-01-26 Astrazeneca Ab 4 (phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
WO2002096912A1 (en) 2001-06-01 2002-12-05 Astrazeneca Ab Novel ligand for nicotinic acetylcholine receptors useful in therapy
DE60233414D1 (de) 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
ES2399977T3 (es) 2001-09-27 2013-04-04 Ramot At Tel Aviv University Ltd. Conjugado de perfenazina o flufenazina con ácidos carboxílicos
JP4523775B2 (ja) 2002-04-18 2010-08-11 アストラゼネカ・アクチエボラーグ 複素環化合物
BR0309342A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0309343A (pt) 2002-04-18 2005-02-15 Astrazeneca Ab Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
SE0202465D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New compounds
SE0202430D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab New Compounds
SE0202598D0 (sv) 2002-09-02 2002-09-02 Astrazeneca Ab Alpha-7 Nicotinic receptor agonists and statins in combination
KR20050048633A (ko) 2002-09-18 2005-05-24 에프엠씨 코포레이션 살충성 트라이사이클릭 유도체
WO2004056182A1 (en) 2002-12-20 2004-07-08 Basf Aktiengesellschaft Pesticidal dibenzo(hetero)azepine derivatives
WO2004064753A2 (en) 2003-01-23 2004-08-05 Acadia Pharmaceuticals Inc Use of n-desmethylclozapine to treat human neuropsychiatric disease
WO2004076431A1 (en) 2003-02-22 2004-09-10 Teva Pharmaceutical Industries Ltd. Synthesis of quetiapine and pharmaceutically acceptable salts thereof
DE10310196A1 (de) 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
JP2006523707A (ja) 2003-04-15 2006-10-19 アストラゼネカ アクツィエボラーグ 治療化合物
US20060217366A1 (en) * 2003-07-02 2006-09-28 Astrazeneca Ab Method of treating schizophrenia and other disorders
PL195728B1 (pl) 2003-07-18 2007-10-31 Helm Ag Sposób wytwarzania 11-(1-piperazynylo)dibenzo[b,f][1,4]tiazepiny
RU2394030C2 (ru) * 2003-12-22 2010-07-10 Акадиа Фармасьютикалз Инк. АМИНОЗАМЕЩЕННЫЕ АНАЛОГИ ДИАРИЛ [a,d] ЦИКЛОГЕПТЕНА В КАЧЕСТВЕ МУСКАРИНОВЫХ АГОНИСТОВ И СПОСОБЫ ЛЕЧЕНИЯ ПСИХОНЕВРОЛОГИЧЕСКИХ РАССТРОЙСТВ
BRPI0417749A (pt) * 2003-12-22 2007-04-10 Acadia Pharm Inc composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas
US20060063754A1 (en) 2004-09-21 2006-03-23 Edgar Dale M Methods of treating a sleep disorder
BRPI0517423A (pt) 2004-12-27 2008-10-07 Astrazeneca Ab composto, composição farmacêutica, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com disfunção do glutamato em um animal, e, uso em um composto
EP1838325A1 (en) * 2005-01-07 2007-10-03 AstraZeneca AB NEW USE OF 11-PIPERAZIN-1-YLDIBENZO [b,f][1,4]THIAZEPINE OR ITS PHARMACEUTICALLY ACCEPTABLE SALT AND TO ORAL PHARMACEUTICAL COMPOSITIONS
US20060252744A1 (en) * 2005-04-04 2006-11-09 Burstein Ethan S Use of N-desmethylclozapine and related compounds as dopamine stabilizing agents
WO2007053618A1 (en) * 2005-10-31 2007-05-10 Acadia Pharmaceuticals Inc. Prodrugs of muscarinic agonists and methods of treatment of neuropsychiatric disorders
WO2008079847A1 (en) 2006-12-20 2008-07-03 Astrazeneca Ab (Se/Se) Compounds and uses thereof
EP2114940A1 (en) 2007-02-09 2009-11-11 AstraZeneca AB Aza-isoindolones and their use as metabotropic glutamate receptor potentiators - 613
US7491871B2 (en) 2007-04-25 2009-02-17 Stine Seed Farm, Inc. Soybean cultivar S060299
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
CA2728675A1 (en) * 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof

Also Published As

Publication number Publication date
ME01516B (me) 2014-04-20
CR11860A (es) 2011-02-25
AU2009260905A1 (en) 2009-12-23
ZA201100488B (en) 2011-10-26
JP2014098006A (ja) 2014-05-29
SI2307389T1 (sl) 2013-04-30
CU23884B1 (es) 2013-04-19
EP2307389B1 (en) 2013-01-23
IL210081A (en) 2013-12-31
EP2307389A4 (en) 2012-04-11
NZ590616A (en) 2012-09-28
PT2307389E (pt) 2013-03-28
DOP2010000393A (es) 2011-01-31
HRP20130234T1 (hr) 2013-04-30
SV2010003769A (es) 2011-05-20
DK2307389T3 (da) 2013-04-02
CN102131791B (zh) 2014-12-24
TW201002702A (en) 2010-01-16
CN102131791A (zh) 2011-07-20
EA201001889A1 (ru) 2011-08-30
MX2010014203A (es) 2011-02-22
JP2011524898A (ja) 2011-09-08
HK1156308A1 (en) 2012-06-08
KR20110019781A (ko) 2011-02-28
WO2009154563A1 (en) 2009-12-23
IL229560A (en) 2015-07-30
ES2402084T3 (es) 2013-04-26
RS52703B (sr) 2013-08-30
US8158618B2 (en) 2012-04-17
HN2010002683A (es) 2013-01-15
BRPI0914231A2 (pt) 2015-11-03
PL2307389T3 (pl) 2013-05-31
PE20110029A1 (es) 2011-02-11
CU20100252A7 (es) 2011-11-15
CL2010001471A1 (es) 2011-05-06
TWI488854B (zh) 2015-06-21
US20090318415A1 (en) 2009-12-24
IL229560A0 (en) 2014-01-30
ECSP10010698A (es) 2011-01-31
JP5468068B2 (ja) 2014-04-09
CA2728675A1 (en) 2009-12-23
AR072200A1 (es) 2010-08-11
UA105903C2 (uk) 2014-07-10
US20120202991A1 (en) 2012-08-09
US20110160184A1 (en) 2011-06-30
EP2307389A1 (en) 2011-04-13
MY157518A (en) 2016-06-15
NI201000224A (es) 2012-03-19
US8653257B2 (en) 2014-02-18
IL210081A0 (en) 2011-02-28
AU2009260905B2 (en) 2012-08-23
UY31919A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
CY1117197T1 (el) Ενωσεις τριαζολοπυριδινης ως αναστολεις της κινασης ριμ
CY1122712T1 (el) ΧΡΗΣΗ ΠΑΡΑΓΩΓΩΝ ΠΥΡΑΖΟΛΟΠΥΡΙΜΙΔΙΝΗΣ ΓΙΑ ΤΗ ΘΕΡΑΠΕΙΑ ΣΧΕΤΙΚΩΝ ΜΕ PI3Kδ ΔΙΑΤΑΡΑΧΩΝ
UY34451A (es) Derivados de uracilo como inhibidores de la quinasa axl y c-met
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1121460T1 (el) Διαμορφωση του μεταγωγεα σηματος και του ενεργοποιητη εκφρασης της μεταγραφης 3 (stat3)
JO3073B1 (ar) مثبطات ثنائية ملتحمة ثلاثية الحلقة ل cdk 4/6 و flt3
CY1117374T1 (el) Παραγωγα ιμιδαζοπυριδινης, διαδικασια για την παρασκευη αυτων και θεραπευτικη χρηση αυτων
CY1120318T1 (el) Υποκατεστημενες βενζυλινδαζολες για χρηση ως αναστολεις κινασης bub1 στη θεραπευτικη αντιμετωπιση υπερπολλαπλασιαστικων ασθενειων
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
CY1122613T1 (el) Παραγωγα 4-οξο-3,4-διυδρο-1,2,3-βενζοτριαζινης ως ρυθμιστες toy gpr139
CO6270257A2 (es) Derivados de piridazinona
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
CY1121248T1 (el) Πολυμορφικες μορφες κι αλατα 6-(1h-ινδολ-4-υλ)-4-(5-{[4-(1-μεθυλαιθυλο)-1-πιπεραζινυλ]μεθυλο}-1,3-οξαζολ-2-υλ)-1η-ινδαζολιου ως αναστολεις ρi3κ για χρηση στη θεραπεια π.χ. αναπνευστικων διαταραχων
EA201071234A1 (ru) Производные изохинолинона в качестве nk3 антагонистов
CY1120111T1 (el) Αντιβακτηριακα παραγωγα 2η-ινδαζολης
IN2012DN01983A (enExample)
BR112016026787A8 (pt) Derivados de quinzaolina-4(3h)-ona antibacterianos
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
EA201001889A1 (ru) Производные дибензотиазепина и их применение
DOP2011000082A (es) Sales de n-[6-(cis-2,6-dimetil-morfolin-4-il)-piridin-3-il]-2-metil-4-(trifluorometoxi)-[1,1'-bifenil] -3-carboxamida
CY1117855T1 (el) Διαδικασια για τη συνθεση των παραγωγων 3,6-διυδρο-1,3,5-τριαζινης